L\u2019autorit\u00e9 am\u00e9ricaine de r\u00e9gulation des produits de sant\u00e9 (FDA) a actualis\u00e9 son \u00e9valuation de certains dispositifs de perfusion fabriqu\u00e9s par ICU Medical, en indiquant que ces dispositifs peuvent entra\u00eener des probl\u00e8mes de sant\u00e9 temporaires ou r\u00e9versibles et, plus rarement, des probl\u00e8mes graves, tout en restant jug\u00e9s utilisables dans le cadre des pratiques cliniques standard. Les produits concern\u00e9s sont des dispositifs de perfusion intraveineuse avec chambre compte-gouttes : jeux d\u2019administration Plum, dispositifs de perfusion par gravit\u00e9 non d\u00e9di\u00e9s, dispositifs IV avec chambres compte-gouttes et dispositifs d\u2019oncologie avec chambres compte-gouttes.<\/p>\n
En mai et juin 2026, ICU Medical a signal\u00e9 \u00e0 ses clients l\u2019observation de petits points noirs, de d\u00e9colorations sur la paroi interne des chambres compte-gouttes et de particules \u00e0 l\u2019int\u00e9rieur de ces chambres sur certains sets de perfusion. Ces constats ont soulev\u00e9 des interrogations sur un \u00e9ventuel risque de contamination biologique ou de migration de particules dans le circuit de perfusion.<\/p>\n
Apr\u00e8s enqu\u00eate (analyse d\u2019\u00e9chantillons retourn\u00e9s, analyses de laboratoire, tests en conditions simul\u00e9es d\u2019utilisation et inspection des stocks), ICU Medical a conclu que les d\u00e9colorations observ\u00e9es sont intrins\u00e8ques au PVC utilis\u00e9 pour fabriquer les chambres compte-gouttes, restent ench\u00e2ss\u00e9es dans la paroi, ne correspondent ni \u00e0 une contamination biologique ni \u00e0 un mat\u00e9riau \u00e9tranger, n\u2019entrent pas dans le circuit de perfusion, ne se d\u00e9tachent pas dans les conditions normales d\u2019utilisation et n\u2019affectent ni l\u2019int\u00e9grit\u00e9 structurelle ni la performance du dispositif.<\/p>\n
Sur cette base, et dans une lettre de mise \u00e0 jour finale dat\u00e9e du 28 juillet 2026, ICU Medical recommande : de poursuivre l\u2019utilisation des produits conform\u00e9ment \u00e0 leur usage pr\u00e9vu, aux instructions d\u2019utilisation et aux proc\u00e9dures cliniques \u00e9tablies dans les \u00e9tablissements ; de proc\u00e9der, comme en pratique clinique standard, \u00e0 une inspection visuelle syst\u00e9matique des dispositifs avant utilisation ; de mettre \u00e0 l\u2019\u00e9cart tout dispositif pr\u00e9sentant des particules libres dans le trajet de fluide et de contacter ICU Medical pour retour et investigation de l\u2019\u00e9chantillon ; de diffuser l\u2019information \u00e0 tous les utilisateurs potentiels du dispositif. Aucun retour syst\u00e9matique de produit n\u2019est jug\u00e9 n\u00e9cessaire.<\/p>\n
Pour le suivi de politiques publiques, ce cas illustre le r\u00f4le de la FDA dans la r\u00e9\u00e9valuation du niveau de risque de dispositifs d\u00e9j\u00e0 commercialis\u00e9s, ainsi que la gestion par le fabricant d\u2019un signal de qualit\u00e9 produit via communications cibl\u00e9es et recommandations d\u2019usage plut\u00f4t que par un retrait. Les \u00e9l\u00e9ments de langage insistent sur le maintien de l\u2019utilisation clinique avec vigilance renforc\u00e9e et sur la transparence vis-\u00e0-vis des professionnels de sant\u00e9. (contenu r\u00e9sum\u00e9 en fran\u00e7ais par l’IA)\u00a0\u200bLire la Suite<\/a><\/p>","protected":false},"excerpt":{"rendered":" L\u2019autorit\u00e9 am\u00e9ricaine de r\u00e9gulation des produits de sant\u00e9 (FDA) a actualis\u00e9 son \u00e9valuation de certains dispositifs de perfusion fabriqu\u00e9s par ICU Medical, en indiquant que ces dispositifs peuvent entra\u00eener des […]<\/p>\n","protected":false},"author":1,"featured_media":17780,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[7],"tags":[260,227,226],"class_list":["post-19884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicaments-et-produits-de-sante","tag-fda","tag-ia","tag-sources-etrangeres"],"_links":{"self":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/19884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19884"}],"version-history":[{"count":0,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/posts\/19884\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=\/wp\/v2\/media\/17780"}],"wp:attachment":[{"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veilles-affaires-sociales.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}